The European Investment Fund (EIF), together with institutions in Germany and Austria, has launched a new fund to support early-stage drug discovery projects sourced predominantly from academic institutions in both countries.
The fund, KHAN Technology Transfer Fund I GmbH (KHAN-I), is based in Dortmund, Germany and has capital of €60 million. Half of the initial capital, or €30 million, is being provided by the EIF, which is part of the European Investment Bank Group. The fund will invest in either new project ideas covered by collaboration agreements or in start-up companies.